Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$1.67 - $3.33 $1,135 - $2,264
680 Added 96.05%
1,388 $2,000
Q3 2023

Oct 30, 2023

BUY
$1.67 - $3.33 $1,135 - $2,264
680 Added 96.05%
1,388 $2,000
Q2 2023

May 21, 2024

SELL
$2.83 - $4.94 $56 - $98
-20 Reduced 2.75%
708 $2,000
Q2 2023

Jul 27, 2023

SELL
$2.83 - $4.94 $56 - $98
-20 Reduced 2.75%
708 $2,000
Q1 2023

May 21, 2024

BUY
$4.89 - $12.27 $889 - $2,233
182 Added 33.33%
728 $3,000
Q1 2023

Apr 27, 2023

BUY
$4.89 - $12.27 $889 - $2,233
182 Added 33.33%
728 $4,000
Q4 2022

May 21, 2024

BUY
$8.88 - $12.77 $4,848 - $6,972
546 New
546 $5,000
Q4 2022

Jan 31, 2023

BUY
$8.88 - $12.77 $381 - $549
43 Added 8.55%
546 $6,000
Q3 2022

Oct 21, 2022

BUY
$8.24 - $12.56 $4,144 - $6,317
503 New
503 $5,000

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14.5M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.